Cellular Topoisomerase I Inhibition and Antiproliferative Activity by MJ-III-65 (NSC 706744), an Indenoisoquinoline Topoisomerase I Poison
about
Immunodetection of human topoisomerase I-DNA covalent complexesDNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial InhibitionSynthesis and Evaluation of Indenoisoquinoline Topoisomerase I Inhibitors Substituted with Nitrogen HeterocyclesPhenotypic screening reveals topoisomerase I as a breast cancer stem cell therapeutic targetThe indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.Proteomic analysis of nuclei isolated from cancer cell lines treated with indenoisoquinoline NSC 724998, a novel topoisomerase I inhibitor.Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.A novel DNA topoisomerase I inhibitor with different mechanism from camptothecin induces G2/M phase cell cycle arrest to K562 cells.Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity.Genomic profiling in CEPH cell lines distinguishes between the camptothecins and indenoisoquinolines.Phosphorylation and stabilization of topoisomerase IIα protein by p38γ mitogen-activated protein kinase sensitize breast cancer cells to its poisons.Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assayIndotecan (LMP400) and AM13-55: two novel indenoisoquinolines show potential for treating visceral leishmaniasis.Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1)Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons.Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures.A Facile method to transform trans-4-carboxy-3,4-dihydro-3-phenyl- 1(2H)-isoquinolones to indeno[1,2-c]isoquinolinesA systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.Total synthesis and biological evaluation of 22-hydroxyacuminatine.Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.Investigation of the Structure-Activity Relationships of Aza-A-Ring Indenoisoquinoline Topoisomerase I Poisons.Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of noncamptothecin topoisomerase I (Top1) inhibitors.Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells.Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discoveryLuminescent cyclometalated platinum(II) complex forms emissive intercalating adducts with double-stranded DNA and RNA: differential emissions and anticancer activities.TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells.Induction of cell death by a novel naphthoquinone containing a modified anthracycline ring system.DNA cleavage assay for the identification of topoisomerase I inhibitors.Chronic reduction in cardiac output induces hypoxic signaling in larval zebrafish even at a time when convective oxygen transport is not required.Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant gene associated with Angelman syndrome
P2860
Q27324108-F6582919-16D4-48C0-A9DE-0D653A126347Q29400901-E7A6C0C4-3F39-4F5D-B9A1-E016FFFA809EQ29544329-C629C7DF-0095-40E1-9197-9F232E4429CBQ30419235-02B221CB-AD1A-4E94-B276-5FFEA9C4BC5BQ33925798-8D8A112F-1C8E-45B2-8B82-DDD45DB8B7AFQ34049926-7545C573-91FE-450E-BB9A-F53AD3D7D078Q34316288-11D904AB-8D68-46F1-9B19-EAF7955F2BDEQ34442265-0AF18F04-C921-4397-AB87-74F0506E90A3Q35152039-590E6430-F776-4154-9B07-2EF07C1D1687Q35318071-C14F4C79-B535-4846-B1D6-CFC5EC7E0063Q35371337-96D130C1-242D-4E27-A84E-0CDD82A9F1D6Q36270038-C7CE4D1C-10AC-41A6-9790-17CD0CAE3D44Q36276947-9DB5E4A1-5B87-492C-8AF6-65C2AAC1BA26Q36524994-69FCE7B3-AD88-402F-8ADF-16557194888AQ36680167-B791158E-1468-4488-B8AA-FA22F1E373DBQ36844392-A15FCD87-202F-4516-8CAD-8309E4E9FD89Q36853884-EB06968A-BA30-44DE-BEA5-76E06DE0171AQ36853889-AE252555-8C0B-4285-A87B-80157EA758ADQ36867857-096556F8-BDEA-43CF-B439-509CFFDCF93EQ37574005-409D6EB1-6112-4C37-B198-96E20731EA53Q37652521-34B2521F-FD77-4B25-8159-602E984C9BB6Q37695391-0B892244-67F5-4138-BBB0-CE567E241F08Q37697431-82551756-025F-4110-9215-3821CEEA9EC3Q38291539-2C6B759F-3A64-4462-A46C-23C599E27697Q38973433-61B64DB8-3E4D-4A17-AE3E-599758426966Q39190645-9515AF4B-9977-4F99-8C62-48C44EF9628AQ39491036-A4A1FD0F-010B-45F3-A9F9-2DE9E3F8F1C7Q46312378-CD0DA5D7-78AB-46FE-9C87-ECCFCA859A10Q50574131-7467797D-D8E7-4883-B880-569C398494C4Q57168803-F9FD921E-B3FD-434D-BDEC-C295F158C59B
P2860
Cellular Topoisomerase I Inhibition and Antiproliferative Activity by MJ-III-65 (NSC 706744), an Indenoisoquinoline Topoisomerase I Poison
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Cellular Topoisomerase I Inhib ...... inoline Topoisomerase I Poison
@ast
Cellular Topoisomerase I Inhib ...... inoline Topoisomerase I Poison
@en
type
label
Cellular Topoisomerase I Inhib ...... inoline Topoisomerase I Poison
@ast
Cellular Topoisomerase I Inhib ...... inoline Topoisomerase I Poison
@en
prefLabel
Cellular Topoisomerase I Inhib ...... inoline Topoisomerase I Poison
@ast
Cellular Topoisomerase I Inhib ...... inoline Topoisomerase I Poison
@en
P356
P1476
Cellular Topoisomerase I Inhib ...... inoline Topoisomerase I Poison
@en
P2093
P304
P356
10.1124/MOL.104.003889
P577
2004-11-17T00:00:00Z